Mofezolac (N-22) の咽頭炎・喉頭炎・扁桃炎に対する臨床評価

Ibuprofenを対照とした二重盲検比較試験―

抄録

The clinical usefulness of Mofezolac (N-22), a new non-steroidal anti inflammatory agent, was evaluated in comparison with Ibuprofen (IP) by a double-blind comparative study on patients with pharyngitis, laryngitis and tonsillitis.
Daily dose was 225 mg (3 times/day) in N-22 group and 600 mg (3 times/day) in IB group. The results are summarized as follows.
A total of 215 cases were subjected for the study, of which 108 were for N-22 group and 107 were for IP group. No significant difference in patient back-ground factors was recognized between N-22 and IP group.
Of a total of 183 efficacy evaluable cases (N-22; 89, IP; 94), 65.2% of N-22 group and 57.4% of IP group were rated “≥ moderately improved” in final global improvement rate, no significant difference between N-22 and IP groups.
In the rating “Significant improvement” with respect to the “Improvement by Symptom”, N-22 group showed an improvement higher than IB group in the categories of both analgesic effect (laryngitis and pharyngitis, etc) .
No significant difference between the two groups was recognized in Overall Safety rating. N-22 group caused side-effects in 8 cases (8.4%) and IP group in 9 cases (9.4%), most of which were observed an gastrointestinal symptoms found not clinically serious.
Of a total of 183 utility evaluable cases (N-22; 89, IP; 94), 62.9% of N-22 group and 54.3% of IP group were rated “≥moderately useful” in global utility rate, with no significant difference between N-22 and IP groups.
From the foregoing study, N-22 is found clinically useful to pharyngitis, laryngitis and tonsillitis with pain.